394.20
+1.09%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About F D C
Its shares trade on NSE under the ticker FDC.NS. It has been listed since 7 August 1997. In the fiscal year to 31 March 2025, it reported revenue of ₹21.08bn and net income of ₹2.67bn. At that date it held total assets of ₹27.14bn and shareholders' equity of ₹22.81bn.
FDC Ltd. engages in the business of pharmaceutical. The company is headquartered in Mumbai, Maharashtra. The firm manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. The company also manufactures oral rehydration salts (ORS) and specialized formulations. The company has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. The company has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Aug 1997
- Employees
- 6,372
- Website
- fdcindia.com ↗
Leadership
Pay as last reported
- Mr. Uday GurkarNon-Executive Independent Chairman of the Board₹1.1m
- Mr. Vishal ShahChief Financial Officer
- Mr. Ameya ChandavarkarChief Executive Officer - International Business, Executive Director, since 2021₹24.1m
- Ms. Varsharani KatreCompliance Officer, Company Secretary
- Mr. Mohan ChandavarkarManaging Director, Executive Director, since 2004₹44.8m
- Mr. Nandan ChandavarkarJoint Managing Director, Executive Director₹37.3m
- Mr. Ashok ChandavarkarExecutive Director, since 1987₹20.7m
- Ms. Nomita ChandavarkarNon-Executive Non-Independent Director, since 2015₹850,000
- Mr. Vijay BhattNon-Executive Independent Director₹1.1m
- Dr. Mahesh BijlaniNon-Executive Independent Director₹950,000
- Dr. Charuta MandkeNon-Executive Independent Director₹700,000
- Mr. Vijay ManiarNon-Executive Independent Director₹1.2m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 51
- Social
- 58
- Governance
- 67
- Direct emissions (scope 1)
- 1,536.65 t
- Energy emissions (scope 2)
- 20,929.64 t
- Women in the workforce
- 3.34885%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- FDC Ltd. manufactures APIs including Albuterol Sulfate and Flurbiprofen Sodium in Mumbai.
- The company has a strong presence in therapeutic segments like anti-infectives and respiratory treatments.
- FDC Ltd. offers functional foods and beverages alongside pharmaceutical products.
Weaknesses
- FDC Ltd. has no manufacturing plants outside Mumbai for its APIs production.
- The company's brand portfolio includes Zifi and Electral but lacks global recognition.
- FDC Ltd. does not have a significant presence in the anti-diabetes segment.
Opportunities
- FDC Ltd. can expand its functional food and beverage range in the Indian market.
- The company can leverage its APIs like Bromhexine Hydrochloride for new therapeutic applications.
- FDC Ltd. has potential to grow in the ophthalmological segment with existing brands.
Threats
- FDC Ltd. faces competition from other Indian pharmaceutical companies in Mumbai.
- The company's reliance on Mumbai for manufacturing poses supply chain risks.
- FDC Ltd. must comply with evolving Indian pharmaceutical regulations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.